Centrum Medyczne All-Med Badania Kliniczne — Clinical Trial Site

70 Registered trials

17 Currently recruiting

Organisation

Centrum Medyczne All-Med Badania Kliniczne

Location

Cracow, Poland

Identifier

ORG-100044304

Address

Ul. Henryka Sienkiewicza 23, 30-033, Poland

Departments

-
#412: Centrum Medyczne All-Med Badania Kliniczne
#45014
40092: Centrum Medyczne All-Med Badania Kliniczne
5201: Pulmonology
616005: pulmonology
Alergologia
All-Med
Centrum Medyczne "All-Med" BADANIA KLINICZNE
CENTRUM MEDYCZNE „ALL-MED”
Centrum Medyczne All-Med Badania Kliniczne
Centrum Medyczne All-Med, ul. Henryka Sienkiewicza 23, 30-03
Centrum Medyczne All-Med, ul. Henryka Sienkiewicza 23, 30-03( #1)
Centrum Medyczne All-Med. Badania Kliniczne
Dermatology
Dermatology Department
N/A
NA
Not applicable
Outpatient Clinic

Clinical trials at this site (70)

Search interface

An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation

2024-510810-33-00 Severe eosinophilic asthma 5 2024-10-14
A randomized, double-blind, placebo-controlled clinical endpoint bioequivalence study to evaluate the therapeutic equivalence and safety of … Not authorised

2025-521565-27-00 Asthma 5
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis (ADAPTIVE) Pending

2024-520117-50-00 Atopic Dermatitis 4
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending

2025-523510-87-00 Obesity 5
Efficacy and Safety of KAI-9531 compared with Semaglutide in Participants Living With Obesity Who Do Not Have Diabetes Pending

2025-523511-11-00 Obesity 5
BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending

2025-524289-56-00 Asthma 6
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting

2025-523104-71-00 Obesity or Overweight Without Type 2 Diabetes 5 2026-05-08
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting

2025-522782-30-00 CCI 3 2026-04-07
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
A Phase 2 Study of Lesigercept (YH35324) in Adult Patients with Chronic Spontaneous Urticaria (CLEAR) Recruiting

2025-524006-14-00 Chronic Spontaneous Urticaria 4 2026-04-20
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting

2025-522583-32-00 Cold-Induced Urticaria and Symptomatic Dermographism 5 2026-04-13
A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting

2025-522578-35-00 Atopic Dermatitis 4 2026-03-30
A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma Recruiting

2025-522640-41-00 Asthma 4 2026-02-13
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adoles… Recruiting

2024-518156-24-00 Atopic Dermatitis 5 2025-11-10
A Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior… Recruiting

2024-513112-99-00 Active Psoriatic Arthritis Stratified by Prior Biologic 5 2025-06-13
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis Recruiting

2024-517284-23-00 Active Psoriatic Arthritis 5 2025-04-23
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO… Recruiting

2023-508760-29-00 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) 5 2024-10-21
Efficacy and safety of subcutaneous dupilumab for the treatment of adult participants with chronic pruritus of unknown origin (CPUO) Recruiting

2023-508879-36-00 Pruritus 5 2022-04-28
Long-term safety and efficacy evaluation of lunsekimig in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who comp… Ended

2024-515912-27-00 Chronic rhinosinusitis with nasal polyps 4 2025-12-08